A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Ongoing, but not recruiting

1

Start Date 12/01/2013

Age of Trial (yrs) 11.3

Gleevec-resistant

MEK inhibitor + PD-L1 inhibitor

Block related tumor path + stimulate immune system

GIST not specified. GIST patients known to be enrolled.

GP28363

Hoffmann-La Roche

Reference Study ID Number: GP28363 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. Only) global rochegenentechtrials@roche.com

Oral Intravenous

A Phase Ib, open-label, multicenter study designed to assess the safety, tolerability, and pharmacokinetics of coadministration of MPDL3280A and of cobimetinib in patients with metastatic or locally advanced cancer for which no standard of care exists.